Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19903873 | 0.84 | ALDH1A1 (0.32) | ALDH1A1LMNATSHRKMT2AHSD17B10 | |
| SCHEMBL7123770 | 0.81 | ALDH1A1 (0.37) | ALDH1A1LMNATSHRKMT2AHSD17B10 | |
| SCHEMBL1628557 | 0.76 | — | — | |
| SCHEMBL9358053 | 0.73 | ALDH1A1 (0.35) | ALDH1A1LMNATSHRKMT2AHSD17B10 | |
| SCHEMBL5160089 | 0.73 | ALDH1A1 (0.35) | ALDH1A1LMNATSHRKMT2AHSD17B10 | |
| SCHEMBL431589 | 0.69 | — | — | |
| SCHEMBL424899 | 0.69 | — | — | |
| SCHEMBL10975038 | 0.69 | — | — | |
| SCHEMBL11283022 | 0.69 | ALDH1A1 (0.37) | ALDH1A1LMNATSHRKMT2AHSD17B10 | |
| SCHEMBL10399375 | 0.69 | ALDH1A1 (0.37) | ALDH1A1LMNATSHRKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278909-B2 | Amide-extended crosslinking compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9246187-B2 | Non-aqueous electrolyte for lithium-ion battery | UCHICAGO ARGONNE, LLC (US) | 2016-01-26 | — | — | US | disclosed |
| US-9218915-B2 | Non-aqueous electrolyte for lithium-ion battery | UCHICAGO ARGONNE, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140272607-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM-ION BATTERY | UCHICAGO ARGONNE LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140186721-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM-ION BATTERY | UCHICAGO ARGONNE, LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-8513375-B2 | Imide-linked maleimide and polymaleimide compounds | DESIGNER MOLECULES, INC. | 2013-08-20 | — | — | US | disclosed |
| US-20120088160-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM-ION BATTERY | UCHICAGO ARGONNE, LLC | 2012-04-12 | — | — | US | disclosed |
| US-20110130485-A1 | IMIDE-LINKED MALEIMIDE AND POLYMALEIMIDE COMPOUNDS | DESIGNER MOLECULES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7884174-B2 | condensation of appropriate anhydrides with appropriate diamines to give amine terminated compounds, then condensed with excess maleic anhydride to yield imide-extended maleimide compounds | DESIGNER MOLECULES, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
| EP-2176209-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009012954-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009012954-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-01-29 | — | — | WO | disclosed |
| US-20080075961-A1 | Imide-linked maleimide and polymaleimide compounds | DESIGNER MOLECULES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-6603041-B2 | Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells | CELLTECH R & D LIMITED (GB) | 2003-08-05 | — | — | US | disclosed |
| EP-1315725-A1 | BICYCLIC ENAMIDE DERIVATIVES BEING INTEGRIN INHIBITORS | Celltech R & D Limited (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-20020072607-A1 | Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells | CELLTECH R&D, LTD. (GB) | 2002-06-13 | — | — | US | disclosed |
| WO-2002020522-A1 | BICYCLIC ENAMIDE DERIVATIVES BEING INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| US-3984455-A | Prostaglandin E1 analogs | THE UPJOHN COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130485-A1 | IMIDE-LINKED MALEIMIDE AND POLYMALEIMIDE COMPOUNDS | MEN1, PBRM1, PAICS | ALDH1A1 3665/4885LMNA 1617/4885TSHR 4587/4885 |
| US-20020072607-A1 | Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells | ITGB2, VCAM1, ITGB1 | ALDH1A1 1359/4885LMNA 2667/4885TSHR 1154/4885 |
| US-20120088160-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM-ION BATTERY | VDAC1, VDAC2, CA2 | ALDH1A1 1200/4885LMNA 692/4885TSHR 3073/4885 |
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, ESR2 | ALDH1A1 3055/4885LMNA 3050/4885TSHR 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.